- Home
- RVTY
RVTY
Revvity Inc.
as 07-26-2024 4:00pm EST
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Upcoming Earnings Alert:
Get ready for potential market movements as Revvity Inc. RVTY prepares to release earnings report on 29 Jul 2024.
| Founded: | 1937 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 13.4B | IPO Year: | N/A |
| Target Price: | $119.00 | AVG Volume (30 days): | 881.9K |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 1.22 | EPS Growth: | -83.95 |
| 52 Week Low/High: | $79.50 - $129.07 | Next Earning Date: | 07-29-2024 |
| Revenue: | $2,725,626,000 | Revenue Growth: | -9.85% |
| Revenue Growth (this year): | 3.72% | Revenue Growth (next year): | 6.91% |
Stock Insider Trading Activity of Revvity Inc. (RVTY)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Goldberg Joel S | RVTY | Please See Remarks | Jun 7 '24 | Sell | $110.80 | 1,176 | $130,300.80 | 36,900 | SEC Form 4 |
| Goldberg Joel S | RVTY | Please See Remarks | Jun 7 '24 | Sell | $110.32 | 2,824 | $311,543.68 | 38,076 | SEC Form 4 |
| MICHAS ALEXIS P | RVTY | Director | Feb 29 '24 | Sell | $109.98 | 5,000 | $549,900.00 | 55,604 | SEC Form 4 |
| Vohra Tajinder S | RVTY | Please See Remarks | Feb 27 '24 | Sell | $104.84 | 2,652 | $278,035.68 | 31,379 | SEC Form 4 |
| Vohra Tajinder S | RVTY | Please See Remarks | Feb 27 '24 | Sell | $105.66 | 5,266 | $556,405.56 | 26,113 | SEC Form 4 |
| Goldberg Joel S | RVTY | Please See Remarks | Feb 23 '24 | Sell | $105.13 | 835 | $87,783.55 | 40,900 | SEC Form 4 |
| Singh Prahlad R. | RVTY | Please See Remarks | Feb 23 '24 | Sell | $105.13 | 1,144 | $120,268.72 | 102,270 | SEC Form 4 |
| Goldberg Joel S | RVTY | Please See Remarks | Feb 5 '24 | Sell | $104.08 | 11,546 | $1,201,707.68 | 41,954 | SEC Form 4 |
| Goldberg Joel S | RVTY | Please See Remarks | Feb 5 '24 | Sell | $104.80 | 3,662 | $383,777.60 | 38,292 | SEC Form 4 |
| Goldberg Joel S | RVTY | Please See Remarks | Feb 5 '24 | Sell | $105.66 | 267 | $28,211.22 | 38,025 | SEC Form 4 |
| Singh Prahlad R. | RVTY | Please See Remarks | Feb 5 '24 | Sell | $104.05 | 14,749 | $1,534,633.45 | 99,269 | SEC Form 4 |
| Singh Prahlad R. | RVTY | Please See Remarks | Feb 5 '24 | Sell | $104.80 | 6,468 | $677,846.40 | 92,801 | SEC Form 4 |
Latest Revvity Inc. News
RVTY Breaking Stock News: Dive into RVTY Ticker-Specific Updates for Smart Investing
Zacks
8 hours ago
Revvity (RVTY) to Report Q2 Earnings: What's in the Cards?
Business Wire
a day ago
Revvity Board Declares Quarterly Dividend
Zacks
2 days ago
Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth
Argus Research
3 days ago
RVTY: Rating decreased to a SELL
Zacks
4 days ago
Analysts Estimate Revvity (RVTY) to Report a Decline in Earnings: What to Look Out for
Zacks
7 days ago
Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?
MT Newswires
8 days ago
Bernstein Adjusts Price Target on Revvity to $121 From $123
Argus Research
10 days ago
RVTY: Raising target price to $119.00
Compare RVTY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RVTY Revvity Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.